Physician profile
David Lee
NPI 1114458023
$1,424.54
in general payments reported to CMS, 2019-2025
21 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $717 · 2024: $494 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $277.61 | 2023-2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $232.95 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $124.59 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $104.58 | 2023-2025 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $93.65 | 2023-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $90.40 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.88 | 2023-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $63.75 | 2023-2024 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $60.31 | 2023 | Optimizer |
| Pfizer INC. | $58.43 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $36.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.95 | 2023-2024 | Jardiance |
| Philips North America LLC | $30.23 | 2024 | (Cm9) Amb Mon & Diag Und, (Ck6) Holter |
| Lilly USA, LLC | $24.67 | 2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $22.45 | 2024 | Praluent, Evkeeza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.10 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.22 | 2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $16.33 | 2023 | Onpattro |
| Novo Nordisk INC | $15.77 | 2023 | Wegovy |
| Elite Orthopedics, LLC | $14.66 | 2024 | |
| Organon LLC | $2.42 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.